225 related articles for article (PubMed ID: 20428086)
1. Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines.
Sertel S; Eichhorn T; Simon CH; Plinkert PK; Johnson SW; Efferth T
Molecules; 2010 Apr; 15(4):2886-910. PubMed ID: 20428086
[TBL] [Abstract][Full Text] [Related]
2. Factors determining sensitivity or resistance of tumor cell lines towards artesunate.
Sertel S; Eichhorn T; Sieber S; Sauer A; Weiss J; Plinkert PK; Efferth T
Chem Biol Interact; 2010 Apr; 185(1):42-52. PubMed ID: 20144594
[TBL] [Abstract][Full Text] [Related]
3. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
[TBL] [Abstract][Full Text] [Related]
4. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.
Ciribilli Y; Singh P; Spanel R; Inga A; Borlak J
Oncotarget; 2015 Oct; 6(31):31569-92. PubMed ID: 26427040
[TBL] [Abstract][Full Text] [Related]
5. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
6. Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma.
Llabata P; Mitsuishi Y; Choi PS; Cai D; Francis JM; Torres-Diz M; Udeshi ND; Golomb L; Wu Z; Zhou J; Svinkina T; Aguilera-Jimenez E; Liu Y; Carr SA; Sanchez-Cespedes M; Meyerson M; Zhang X
Mol Cancer Res; 2020 Apr; 18(4):574-584. PubMed ID: 31862696
[TBL] [Abstract][Full Text] [Related]
7. PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells.
Toaldo C; Pizzimenti S; Cerbone A; Pettazzoni P; Menegatti E; Daniela B; Minelli R; Giglioni B; Dianzani MU; Ferretti C; Barrera G
J Cell Mol Med; 2010 Jun; 14(6A):1347-57. PubMed ID: 19912441
[TBL] [Abstract][Full Text] [Related]
8. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.
Wang J; Ma X; Jones HM; Chan LL; Song F; Zhang W; Bae-Jump VL; Zhou C
J Transl Med; 2014 Aug; 12():226. PubMed ID: 25143136
[TBL] [Abstract][Full Text] [Related]
10. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
[No Abstract] [Full Text] [Related]
11. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.
Yang H; Li TW; Ko KS; Xia M; Lu SC
Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells.
Youns M; Efferth T; Reichling J; Fellenberg K; Bauer A; Hoheisel JD
Biochem Pharmacol; 2009 Aug; 78(3):273-83. PubMed ID: 19393226
[TBL] [Abstract][Full Text] [Related]
13. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.
Li Z; Van Calcar S; Qu C; Cavenee WK; Zhang MQ; Ren B
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8164-9. PubMed ID: 12808131
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
Clausen DM; Guo J; Parise RA; Beumer JH; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
J Pharmacol Exp Ther; 2010 Dec; 335(3):715-27. PubMed ID: 20801893
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells.
Wiener Z; Ontsouka EC; Jakob S; Torgler R; Falus A; Mueller C; Brunner T
Exp Cell Res; 2004 Sep; 299(1):227-35. PubMed ID: 15302589
[TBL] [Abstract][Full Text] [Related]
16. c-Myc is regulated by HIF-2α in chronic hypoxia and influences sensitivity to 5-FU in colon cancer.
Wang L; Xue M; Chung DC
Oncotarget; 2016 Nov; 7(48):78910-78917. PubMed ID: 27793037
[TBL] [Abstract][Full Text] [Related]
17. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
Gupta K; Anand G; Yin X; Grove L; Prochownik EV
Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
[TBL] [Abstract][Full Text] [Related]
18. Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers.
Maltais L; Montagne M; Bédard M; Tremblay C; Soucek L; Lavigne P
PLoS One; 2017; 12(3):e0174413. PubMed ID: 28350847
[TBL] [Abstract][Full Text] [Related]
19. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
Efferth T; Volm M
In Vivo; 2005; 19(1):225-32. PubMed ID: 15796179
[TBL] [Abstract][Full Text] [Related]
20. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
Hurlin PJ; Ayer DE; Grandori C; Eisenman RN
Cold Spring Harb Symp Quant Biol; 1994; 59():109-16. PubMed ID: 7587059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
